{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T17:56:06Z","timestamp":1675878966601},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2010,7,17]],"date-time":"2010-07-17T00:00:00Z","timestamp":1279324800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s00115-010-2958-z","type":"journal-article","created":{"date-parts":[[2010,7,15]],"date-time":"2010-07-15T17:39:40Z","timestamp":1279215580000},"page":"940-949","source":"Crossref","is-referenced-by-count":3,"title":["Neurologische Komplikationen der neuroonkologischen Therapie"],"prefix":"10.1007","volume":"81","author":[{"given":"U.","family":"Herrlinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,17]]},"reference":[{"key":"2958_CR1","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1200\/JCO.2008.19.2195","volume":"27","author":"Glas","year":"2009","unstructured":"Glas M, Happold C, Rieger J et al (2009) Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 27:1257\u20131261","journal-title":"J Clin Oncol"},{"key":"2958_CR2","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/JCO.2008.17.8251","volume":"27","author":"Lai","year":"2009","unstructured":"Lai A, Nghiemphu P, Green R et al (2009) Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 27:15s (Abstr 2000)","journal-title":"J Clin Oncol"},{"key":"2958_CR3","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/JCO.2008.19.1445","volume":"27","author":"Gruber","year":"2009","unstructured":"Gruber ML, Raza S, Gruber D, Narayana A (2009) Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: Update progression-free survival, overall survival, and toxicity. J Clin Oncol 27:15s (Abstr 2017)","journal-title":"J Clin Oncol"},{"key":"2958_CR4","doi-asserted-by":"crossref","unstructured":"DeAngelis LM, Posner JB (2008) Neurologic complications of cancer. Oxford University, New York","DOI":"10.1093\/med\/9780195366747.001.0001"},{"key":"2958_CR5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1212\/01.WNL.0000133398.11870.9A","volume":"63","author":"Wit","year":"2004","unstructured":"Wit MC de, Bruin HG de, Eijkenboom et al (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63:535\u2013537","journal-title":"Neurology"},{"key":"2958_CR6","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","volume":"26","author":"Brandes","year":"2008","unstructured":"Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192\u20132197","journal-title":"J Clin Oncol"},{"key":"2958_CR7","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963\u20131972","journal-title":"J Clin Oncol"},{"key":"2958_CR8","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/1097-0142(19941115)74:10<2828::AID-CNCR2820741014>3.0.CO;2-K","volume":"74","author":"Corn","year":"1994","unstructured":"Corn BW, Yousem DM, Scott CB et al (1994) White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83\u201302). Cancer 74:2828\u20132835","journal-title":"Cancer"},{"key":"2958_CR9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/ijc.1016","volume":"96","author":"Chao","year":"2001","unstructured":"Chao ST, Suh JH, Raja S et al (2001) The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 96:191\u2013197","journal-title":"Int J Cancer"},{"key":"2958_CR10","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1212\/WNL.44.11.2020","volume":"44","author":"Glantz","year":"1994","unstructured":"Glantz MJ, Burger PC, Friedman AH et al (1994) Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 44:2020\u20132027","journal-title":"Neurology"},{"key":"2958_CR11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11060-008-9674-6","volume":"90","author":"Happold","year":"2008","unstructured":"Happold C, Ernemann U, Roth P et al (2008) Anticoagulation for radiation-induced neurotoxicity revisited. J Neurooncol 90:357\u2013362","journal-title":"J Neurooncol"},{"key":"2958_CR12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000056426","volume":"70","author":"Leber","year":"1998","unstructured":"Leber KA, Eder HG, Kovac H et al (1998) Treatment of cerebral radionecrosis by hyperbaric oxygen therapy. Stereotact Funct Neurosurg 70:229\u2013236","journal-title":"Stereotact Funct Neurosurg"},{"key":"2958_CR13","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s003309900278","volume":"10","author":"Calabro","year":"2000","unstructured":"Calabro F, Linkins JR (2000) MRI of radiation myelitis: a report of a case treated with hyperbaric oxygen. Eur Radiol 10:1079\u20131084","journal-title":"Eur Radiol"},{"key":"2958_CR14","unstructured":"Levin VA, Bidaut L, Hou P et al (2010) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys (in press)"},{"key":"2958_CR15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/WNL.59.1.40","volume":"59","author":"Armstrong","year":"2002","unstructured":"Armstrong CL, Hunter JV, Ledakis GE et al (2002) Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology 59:40\u201348","journal-title":"Neurology"},{"key":"2958_CR16","unstructured":"Burger PC, Boyko OB (1991) The pathology of central nervous system radiation injury. In: Gutin PH, Leibel SA, Sheline GE (eds) Radiation injury of the nervous system. Raven, New York, pp 191\u2013208"},{"key":"2958_CR17","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1054\/bjoc.2001.2100","volume":"85","author":"Belka","year":"2001","unstructured":"Belka C, Budach W, Kortmann RD, Bamberg M (2001) Radiation induced CNS toxicity \u2013 moelcular and cellular mechanisms. Br J Cancer 85:1233\u20131239","journal-title":"Br J Cancer"},{"key":"2958_CR18","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/nm749","volume":"8","author":"Monje","year":"2002","unstructured":"Monje ML, Mizumatsu S, Fike JR, Palmer TD (2002) Irradiation induces neural precursor-cell dysfunction. Nat Med 8:955\u2013962","journal-title":"Nat Med"},{"key":"2958_CR19","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1182\/blood.V86.11.4184.bloodjournal86114184","volume":"86","author":"Eissner","year":"1995","unstructured":"Eissner G, Kohlhuber F, Grell M et al (1995) Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation andbacterial endotoxin. Blood 86:4184\u20134193","journal-title":"Blood"},{"key":"2958_CR20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/(SICI)1097-0215(19990730)82:3<385::AID-IJC12>3.0.CO;2-5","volume":"82","author":"Quarmby","year":"1999","unstructured":"Quarmby S, Kumar P, Kumar S (1999) Radiation-induced normal tissue injury: role of adhesion molecules in leukocyte-endothelial cell interactions. Int J Cancer 82:385\u2013395","journal-title":"Int J Cancer"},{"key":"2958_CR21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1998.16.3.859","volume":"16","author":"Abrey","year":"1998","unstructured":"Abrey LE, DeAngelis LM, Yahalom J (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16:859\u2013863","journal-title":"J Clin Oncol"},{"key":"2958_CR22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/1097-0142(20010101)91:1<130::AID-CNCR17>3.0.CO;2-8","volume":"91","author":"Herrlinger","year":"2001","unstructured":"Herrlinger U, Schabet M, Brugger W et al (2001) Primary CNS lymphoma 1991\u20131997: outcome and late adverse effects after combined modality treatment. Cancer 91:130\u2013135","journal-title":"Cancer"},{"key":"2958_CR23","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1212\/WNL.62.4.544","volume":"62","author":"Harder","year":"2004","unstructured":"Harder H, Holtel H, Bromberg JEC et al (2004) Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62:544\u2013547","journal-title":"Neurology"},{"key":"2958_CR24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/01.WNL.0000109673.75316.D8","volume":"62","author":"Correa","year":"2004","unstructured":"Correa DD, DeAngelis LM, Shi W et al (2004) Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548\u2013555","journal-title":"Neurology"},{"key":"2958_CR25","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.56.10.1285","volume":"56","author":"Surma-aho","year":"2001","unstructured":"Surma-aho O, Niemel\u00e4 M, Vilkki J et al (2001) Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 56:1285\u20131290","journal-title":"Neurology"},{"key":"2958_CR26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1023\/B:NEON.0000014518.16481.7e","volume":"66","author":"Swennen","year":"2004","unstructured":"Swennen MH, Bromberg JE, Witkamp TD et al (2004) Delayed radiation toxicity after focal or whole brain radiotherapy for low-grade glioma. J Neurooncol 66:333\u2013339","journal-title":"J Neurooncol"},{"key":"2958_CR27","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0140-6736(02)11398-5","volume":"360","author":"Klein","year":"2002","unstructured":"Klein M, Heimans JJ, Aaronson NK et al (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360:1361\u20131368","journal-title":"Lancet"},{"key":"2958_CR28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410360111","volume":"36","author":"Taphoorn","year":"1994","unstructured":"Taphoorn MJ, Schiphorst AK, Snoek F et al (1994) Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 36:48\u201354","journal-title":"Ann Neurol"},{"key":"2958_CR29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/WNL.59.1.40","volume":"59","author":"Armstrong","year":"2002","unstructured":"Armstrong CL, Hunter JV, Ledakis GE et al (2002) Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology 59:40\u201348","journal-title":"Neurology"},{"key":"2958_CR30","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2003.04.172","volume":"21","author":"Brown","year":"2003","unstructured":"Brown PD, Buckner JC, O\u2019Fallon JR et al (2003) Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 21:2519\u20132524","journal-title":"J Clin Oncol"},{"key":"2958_CR31","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1474-4422(09)70204-2","volume":"8","author":"Douw","year":"2009","unstructured":"Douw L, Klein M, Fagel SS et al (2009) Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8:810\u2013818","journal-title":"Lancet Neurol"},{"key":"2958_CR32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11060-008-9728-9","volume":"92","author":"Happold","year":"2009","unstructured":"Happold C, Roth P, Wick W et al (2009) ACNU-based chemotherapy for recurrent glioma in the temozolomide era. J Neurooncol 92:45\u201348","journal-title":"J Neurooncol"},{"key":"2958_CR33","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000201943","volume":"76","author":"Glas","year":"2009","unstructured":"Glas M, Hundsberger T, Stuplich M et al (2009) Nimustine plus teniposide in recurrent glioblastoma. Oncology 76:184\u2013189","journal-title":"Oncology"},{"key":"2958_CR34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/A:1005909318270","volume":"38","author":"Postma","year":"1998","unstructured":"Postma TJ, Groeningen CJ van, Witjes RJ et al (1998) Neurotoxicity of combination chemotherapy with procarbazine, and vincristine (PCV) for recurrent glioma. J Neurooncol 38:69\u201375","journal-title":"J Neurooncol"},{"key":"2958_CR35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1212\/01.wnl.0000194221.89948.a0","volume":"66","author":"Steinbach","year":"2006","unstructured":"Steinbach JP, Blaicher HP, Herrlinger U et al (2006) Surviving glioblastoma for more than 5 years: the patient\u2019s perspective. Neurology 66:239\u2013242","journal-title":"Neurology"},{"key":"2958_CR36","first-page":"17","volume":"45","author":"Subach","year":"1999","unstructured":"Subach BR, Witham TF, Kondziolka D et al (1999) Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 45:17\u201322","journal-title":"Neurosurgery"},{"key":"2958_CR37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/neuonc\/5.2.79","volume":"5","author":"Westphal","year":"2003","unstructured":"Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79\u201388","journal-title":"Neuro Oncol"},{"key":"2958_CR38","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1200\/JCO.2005.04.6078","volume":"24","author":"Bent","year":"2006","unstructured":"Bent MJ van den, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715\u20132722","journal-title":"J Clin Oncol"},{"key":"2958_CR39","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1200\/JCO.2009.23.6497","volume":"27","author":"Wick","year":"2009","unstructured":"Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874\u20135880","journal-title":"J Clin Oncol"},{"key":"2958_CR40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ana.21824","volume":"67","author":"Juergens","year":"2010","unstructured":"Juergens A, Pels H, Rogowski S et al (2010) Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 67:182\u2013189","journal-title":"Ann Neurol"},{"key":"2958_CR41","doi-asserted-by":"crossref","first-page":"7s","DOI":"10.1200\/jco.2010.28.15_suppl.8008","volume":"28","author":"Thiel","year":"2010","unstructured":"Thiel E, Korfel A, Martus P et al (2010) Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lym phoma? The G-PCNSL-SG1 randomized phase IV trial. J Clin Oncol 28:7s (Abstr 8008)","journal-title":"J Clin Oncol"},{"key":"2958_CR42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3171\/2009.5.JNS081738","volume":"112","author":"Aoki","year":"2010","unstructured":"Aoki T, Mizutani T, Nojima K et al (2010) Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme. J Neurosurg 112:50\u201356","journal-title":"J Neurosurg"},{"key":"2958_CR43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1345\/aph.1G114","volume":"40","author":"Patel","year":"2006","unstructured":"Patel PN (2006) Methylene blue for management of Ifosfamide-induced encephalopathy. Ann Pharmacother 40:299\u2013303","journal-title":"Ann Pharmacother"},{"key":"2958_CR44","first-page":"4636","volume":"9","author":"Buesa","year":"2003","unstructured":"Buesa JM, Garc\u00eda-Teijido P, Losa R, Fra J (2003) Treatment of ifosfamide encephalopathy with intravenous thiamin. Clin Cancer Res 9:4636\u20134637","journal-title":"Clin Cancer Res"},{"key":"2958_CR45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11060-004-2929-y","volume":"73","author":"K\u00fcker","year":"2005","unstructured":"K\u00fcker W, Bader P, Herrlinger U et al (2005) Transient encephalopathy after intrathekal methotrexate chemotherapy: diffusion-weighted MRI. J Neurooncol 73:47\u201349","journal-title":"J Neurooncol"},{"key":"2958_CR46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11060-009-0028-9","volume":"97","author":"Ackermann","year":"2010","unstructured":"Ackermann R, Semmler A, Maurer GD et al (2010) Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites. J Neurooncol 97:425\u2013427","journal-title":"J Neurooncol"},{"key":"2958_CR47","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/ana.20495","volume":"57","author":"Herrlinger","year":"2005","unstructured":"Herrlinger U, K\u00fcker W, Uhl M et al (2005) NOA-03 multicenter trial of high-dose methotrexate therapy in primary CNS lymphoma: final report. Ann Neurol 57:843\u2013847","journal-title":"Ann Neurol"},{"key":"2958_CR48","first-page":"3394","volume":"5","author":"Glantz","year":"1999","unstructured":"Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394\u20133402","journal-title":"Clin Cancer Res"},{"key":"2958_CR49","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.mph.0000162527.85024.e9","volume":"27","author":"Bay","year":"2005","unstructured":"Bay A, Oner AF, Etlik O et al (2005) Myelopathy due to intrathecal chemotherapy: report of six cases. J Pediatr Hematol Oncol 27:270\u2013272","journal-title":"J Pediatr Hematol Oncol"},{"key":"2958_CR50","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/mus.1219","volume":"25","author":"Anderson","year":"2002","unstructured":"Anderson SC, Baquis GD, Jackson A et al (2002) Ventral polyradiculopathy with pediatric acute lymphocytic leukemia. Muscle Nerve 25:106\u2013110","journal-title":"Muscle Nerve"},{"key":"2958_CR51","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2006-08-043646","volume":"109","author":"Jabbour","year":"2007","unstructured":"Jabbour E, O\u2019Brien S, Kantarjian H et al (2007) Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 109:3214\u20133218","journal-title":"Blood"},{"key":"2958_CR52","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00277-008-0546-0","volume":"87","author":"Hilgendorf","year":"2008","unstructured":"Hilgendorf I, Wolff D, Junghanss C et al (2008) Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation. Ann Hematol 87:1009\u20131012","journal-title":"Ann Hematol"},{"key":"2958_CR53","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1212\/01.wnl.0000304121.57857.38","volume":"70","author":"Norden","year":"2008","unstructured":"Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779\u2013787","journal-title":"Neurology"},{"key":"2958_CR54","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1158\/0008-5472.CAN-03-3775","volume":"64","author":"Steinbach","year":"2004","unstructured":"Steinbach JP, Klumpp A, Wolburg H et al (2004) Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death. Cancer Res 64:1575\u20131578","journal-title":"Cancer Res"},{"key":"2958_CR55","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/brain\/awp093","volume":"132","author":"Ronellenfitsch","year":"2009","unstructured":"Ronellenfitsch MW, Brucker DP, Burger MC et al (2009) Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Brain 132:1509\u20131522","journal-title":"Brain"},{"key":"2958_CR56","doi-asserted-by":"crossref","unstructured":"Rieger J, Bahr O, Muller K et al (2010) Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol99(1):49\u201356","DOI":"10.1007\/s11060-009-0098-8"},{"key":"2958_CR57","doi-asserted-by":"crossref","unstructured":"Rieger JHE, B\u00e4hr O, Ronellenfitsch MW, Steinbach JP (2010) Bevacizumab-induced diffusion restriction in glioma patients: tumor progression or surrogate marker of hypoxia? J Clin Oncol (in press)","DOI":"10.1200\/JCO.2010.29.2029"},{"key":"2958_CR58","first-page":"553","volume":"6","author":"Winkler","year":"2004","unstructured":"Winkler F, Kozin SV, Tong RT et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553\u2013563","journal-title":"Cancer Cell"},{"key":"2958_CR59","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/sj.onc.1208615","volume":"24","author":"Harris","year":"2005","unstructured":"Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24:2899\u20132908","journal-title":"Oncogene"},{"key":"2958_CR60","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1535-6108(03)00085-0","volume":"3","author":"Pennacchietti","year":"2003","unstructured":"Pennacchietti S, Michieli P, Galluzzo M et al (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347\u2013361","journal-title":"Cancer Cell"},{"key":"2958_CR61","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1096\/fj.04-1918fje","volume":"18","author":"Weinmann","year":"2004","unstructured":"Weinmann M, Jendrossek V, Guner D et al (2004) Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways. FASEB J 18:1906\u20131908","journal-title":"FASEB J"},{"key":"2958_CR62","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1215\/15228517-2009-006","volume":"11","author":"Quant","year":"2009","unstructured":"Quant EC, Norden AD, Drappatz J et al (2009) Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11:550\u2013555","journal-title":"Neuro Oncol"},{"key":"2958_CR63","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722\u20134729","journal-title":"J Clin Oncol"},{"key":"2958_CR64","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2007.12.8710","volume":"25","author":"Martin","year":"2007","unstructured":"Martin G, Bellido L, Cruz JJ (2007) Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 25:3559","journal-title":"J Clin Oncol"},{"key":"2958_CR65","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/annonc\/mdm454","volume":"18","author":"Kapiteijn","year":"2007","unstructured":"Kapiteijn E, Brand A, Kroep J et al (2007) Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 18:1745\u20131747","journal-title":"Ann Oncol"},{"key":"2958_CR66","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1523\/JNEUROSCI.22-15-06401.2002","volume":"22","author":"Wick","year":"2002","unstructured":"Wick A, Wick W, Waltenberger J et al (2002) Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J Neurosci 22:6401\u20136407","journal-title":"J Neurosci"},{"key":"2958_CR67","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"Network","year":"2008","unstructured":"Network TCGA (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061\u20131068","journal-title":"Nature"},{"key":"2958_CR68","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/emboj\/17.3.719","volume":"17","author":"Sibilia","year":"1998","unstructured":"Sibilia M, Steinbach JP, Stingl L et al (1998) A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J 17:719\u2013731","journal-title":"EMBO J"},{"key":"2958_CR69","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00004647-200404000-00005","volume":"24","author":"Jin","year":"2004","unstructured":"Jin K, Sun Y, Xie L et al (2004) Post-ischemic administration of heparin-binding epidermal growth factor-like growth factor (HB-EGF) reduces infarct size and modifies neurogenesis after focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 24:399\u2013408","journal-title":"J Cereb Blood Flow Metab"},{"key":"2958_CR70","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(00)02659-3","volume":"356","author":"Nitsch","year":"2000","unstructured":"Nitsch R, Bechmann I, Deisz RA et al (2000) Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356:827\u2013828","journal-title":"Lancet"},{"key":"2958_CR71","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nm735","volume":"8","author":"Fulda","year":"2002","unstructured":"Fulda S, Wick W, Weller M et al (2002) Smac agonists sensitize for Apo2L\/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8:808\u2013815","journal-title":"Nat Med"},{"key":"2958_CR72","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JF et al (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46\u201354","journal-title":"Neurology"},{"key":"2958_CR73","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/WNL.0b013e3181d5279e","volume":"74","author":"Pace","year":"2010","unstructured":"Pace A, Giannarelli D, Gali\u00e8 E et al (2010) Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology 74:762\u2013766","journal-title":"Neurology"},{"key":"2958_CR74","first-page":"5756","volume":"9","author":"Pisano","year":"2003","unstructured":"Pisano C, Pratesi G, Laccabue D et al (2003) Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 9:5756\u20135767","journal-title":"Clin Cancer Res"},{"key":"2958_CR75","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0304-3959(02)00047-7","volume":"98","author":"Hammack","year":"2002","unstructured":"Hammack JE, Michalak JC, Loprinzi CL et al (2002) Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 98:195\u2013203","journal-title":"Pain"},{"key":"2958_CR76","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1212\/WNL.41.8.1235","volume":"41","author":"Dropcho","year":"1991","unstructured":"Dropcho EJ, Soong SJ (1991) Steroid-induced weakness in patients with primary brain tumors. Neurology 41:1235\u20131239","journal-title":"Neurology"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-010-2958-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-010-2958-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-010-2958-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T01:14:48Z","timestamp":1591492488000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-010-2958-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,17]]},"references-count":76,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["2958"],"URL":"https:\/\/doi.org\/10.1007\/s00115-010-2958-z","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,17]]}}}